Regeneron Pharmaceuticals Collaborates with Telix Pharmaceuticals on Radiopharmaceutical Therapies
Regeneron Pharmaceuticals (REGN) has announced a collaboration with Telix Pharmaceuticals Limited to develop and commercialize next-generation radiopharmaceutical therapies for solid tumors. The deal includes an upfront payment of $40 million to Telix and potential expansion to additional programs. The partnership combines Regeneron's biologics expertise with Telix's radiopharmaceutical platform.
Tickers: $REGN
Topics: biotech collaboration pharmaceuticals precision oncology radiopharmaceutical therapies